Upside case
Bull case
$371+154.5%
PODD would need investors to value it at roughly 57x earnings — about 35x more generous than today's 22x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated Jun 18, 2026
Insulet Corporation (PODD) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
50
analysts
35 bullish · 3 bearish · 50 covering PODD
Strong Buy
0
Buy
35
Hold
12
Sell
3
Strong Sell
0
Consensus Target
$223
+53.1% vs today
Scenario Range
$177 – $371
Model bear to bull value window
Coverage
50
Published analyst ratings
Valuation Context
22.5x
Forward P/E · Market cap $10.2B
PODD price targets
Three scenarios for where PODD stock could go
Current
~$146
Confidence
52 / 100
Updated
Jun 18, 2026
Where we are now
Current · $146
Bear
$177
Base
$282
Bull
$371
Market caseClosest to today
Base case
$282+93.1%
At 43x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$177+21.7%
The bear case assumes sentiment or fundamentals disappoint enough to push PODD down roughly 22% from the current price.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Insulet Corporation
PODD · NASDAQHealthcareMedical - DevicesDecember year-end
Insulet Corporation is a medical device company that makes tubeless insulin pumps for people with diabetes. It generates revenue primarily from sales of its disposable Omnipod pods — which account for the vast majority of its income — along with sales of its handheld controllers and related supplies. Its key competitive advantage is its unique tubeless, waterproof design that offers greater freedom and convenience compared to traditional tube-based insulin pumps.
Market Cap
$10.2B
Revenue TTM
$2.9B
Net Income TTM
$303M
Net Margin
10.4%
PODD Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
92%Exceptional
12 quarters tracked
Revenue Beat Rate
92%Exceptional
vs consensus estimates
Avg EPS Surprise
+37.0%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q3 2025
EPS
$1.17/$0.92
Revenue
$649M/$614M
Q4 2025
EPS
$1.24/$1.14
Revenue
$706M/$678M
Q1 2026
EPS
$1.55/$1.47
Revenue
$784M/$769M
Q2 2026
EPS
$1.42/$1.19
Revenue
$762M/$730M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $1.17/$0.92 | +27.2% | $649M/$614M | +5.7% |
| Q4 2025 | $1.24/$1.14 | +8.8% | $706M/$678M | +4.1% |
| Q1 2026 | $1.55/$1.47 | +5.4% | $784M/$769M | +1.9% |
| Q2 2026 | $1.42/$1.19 | +19.3% | $762M/$730M | +4.4% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$3.3B
+13.5% YoY
FY2
$3.8B
+15.7% YoY
EPS Outlook
FY1
$5.44
+26.2% YoY
FY2
$6.54
+20.2% YoY
Trailing FCF (TTM)$412M
FCF Margin: 14.2%
Next Earnings
August 6, 2026
Expected EPS
$1.45
Expected Revenue
$788M
PODD beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
PODD Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $2.7B
Product Mix
Latest annual revenue by segment or product family
International Omnipod
98.7%
+31.6% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
UNITED STATES
72.1%
+26.2% YoY
Tap, hover, or focus a slice to inspect segment detail.
International Omnipod is the largest disclosed segment at 98.7% of FY 2025 revenue, up 31.6% YoY.
UNITED STATES is the largest reported region at 72.1%, up 26.2% YoY.
PODD Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Slightly expensive versus peers
Fair value est. $121 — implies -17.2% from today's price.
Premium to Fair Value
17.2%
above fair value
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
PODD
41.9x
vs
S&P 500
24.4x
+71% premium
vs Healthcare Trailing P/E
PODD
41.9x
vs
Healthcare
22.1x
+89% premium
vs PODD 5Y Avg P/E
Today
41.9x
vs
5Y Average
66.9x
37% discount
Forward PE
22.5x
S&P 500
18.8x
+20%
Healthcare
18.3x
+23%
5Y Avg
—
—
Trailing PE
41.9x
S&P 500
24.4x
+71%
Healthcare
22.1x
+89%
5Y Avg
66.9x
-37%
PEG Ratio
0.41x
S&P 500
1.66x
-76%
Healthcare
1.59x
-75%
5Y Avg
—
—
EV/EBITDA
18.0x
S&P 500
15.2x
+18%
Healthcare
14.2x
+27%
5Y Avg
47.8x
-62%
Price/FCF
27.1x
S&P 500
20.7x
+31%
Healthcare
18.5x
+46%
5Y Avg
58.6x
-54%
Price/Sales
3.8x
S&P 500
3.1x
+22%
Healthcare
2.6x
+43%
5Y Avg
11.7x
-68%
Dividend Yield
—
S&P 500
1.91%
—
Healthcare
1.50%
—
5Y Avg
—
—
| Metric | PODD | S&P 500 | Healthcare | 5Y Avg PODD |
|---|---|---|---|---|
| Forward PE | 22.5x | 18.8x+20% | 18.3x+23% | — |
| Trailing PE | 41.9x | 24.4x+71% | 22.1x+89% | 66.9x-37% |
| PEG Ratio | 0.41x | 1.66x-76% | 1.59x-75% | — |
| EV/EBITDA | 18.0x | 15.2x+18% | 14.2x+27% | 47.8x-62% |
| Price/FCF | 27.1x | 20.7x+31% | 18.5x+46% | 58.6x-54% |
| Price/Sales | 3.8x | 3.1x+22% | 2.6x+43% | 11.7x-68% |
| Dividend Yield | — | 1.91% | 1.50% | — |
PODD trades above S&P 500 benchmarks on 5 of 6 measured multiples — commands a broad premium across most valuation dimensions.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolPODD Financial Health
Verdict
Strong
PODD generates $412M in free cash flow at a 14.2% margin — 20.1% ROIC signals a durable competitive advantage.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$2.9B
Revenue Growth
TTM vs prior year
+31.9%
Gross Margin
Gross profit as a share of revenue
71.0%
Operating Margin
Operating income divided by revenue
17.5%
Net Margin
Net income divided by revenue
10.4%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$4.31
Free Cash Flow (TTM)
Cash generation after capex
$412M
FCF Margin
FCF as share of revenue — the primary cash quality signal
14.2%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
20.1%
ROA
Return on assets, trailing twelve months
9.6%
Cash & Equivalents
Liquid assets on the balance sheet
$716M
Net Debt
Total debt minus cash
$335M
Debt Serviceability
Net debt as a multiple of annual free cash flow
0.8× FCF
~0.8 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
21.4%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
0.6%
Dividend
—
Buyback
0.6%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$60M
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Declining as buybacks retire shares
70M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pagePODD Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
Medium
Mixed fundamentals
Insulet Corp. demonstrates mixed fundamentals with a B grade, including a 12.0% net profit margin and 7.0% ROE, indicating potential weaknesses in financial performance.
High Risk
Revenue growth uncertainty
Despite a projected long-term price increase, the revenue growth forecast of +147.92% over 5 years may be overly optimistic, introducing execution risk.
Lower
Sector competition
Operating in the competitive Healthcare — Medical Devices sector, Insulet faces risks from established players and innovation pressures.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why PODD Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
Bullish analyst coverage
The Wealth Dynasty Report's Substack highlights a bullish thesis on Insulet Corporation, indicating positive sentiment from analysts.
Strong financial metrics
Insulet Corporation's trailing and forward P/E ratios suggest robust financial performance and growth potential.
Healthcare sector growth
Operating in the medical devices sector, Insulet benefits from the expanding healthcare industry.
Institutional investment interest
Analysis of institutional ownership and smart-money flows indicates strong confidence in Insulet's future.
Narrow moat advantage
Insulet's narrow moat provides a competitive edge, supporting long-term profitability and market position.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
PODD Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$145.76
52W Range Position
2%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$140.63
+3.6% from the low
52-Week High
$354.88
-58.9% from the high
1 Month
-4.41%
3 Month
-36.70%
YTD
-48.5%
1 Year
-51.7%
3Y CAGR
-20.4%
5Y CAGR
-12.3%
10Y CAGR
+17.3%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
PODD vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
22.5x
vs 16.1x median
+39% above peer median
Revenue Growth
+13.5%
vs +9.0% median
+49% above peer median
Net Margin
10.4%
vs 7.7% median
+36% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
POD PODD Insulet Corporation | $10.2B | 22.5x | +13.5% | 10.4% | Buy | +53.1% |
DXC DXCM DexCom, Inc. | $28.0B | 28.0x | +10.0% | 19.3% | Buy | +15.3% |
TND TNDM Tandem Diabetes Care, Inc. | $1.0B | — | +8.6% | -9.2% | Buy | +105.2% |
NVC NVCR NovoCure Limited | $1.6B | — | +9.0% | -25.7% | Buy | +131.1% |
ITG ITGR Integer Holdings Corporation | $3.1B | 15.0x | +8.9% | 7.7% | Buy | +18.7% |
ABT ABT Abbott Laboratories | $153.7B | 16.1x | +9.9% | 31.9% | Buy | +44.2% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
PODD Dividend and Capital Return
PODD returns 0.6% annually — null% through dividends and 0.6% through buybacks.
Dividend UnknownFCF Unknown
Total Shareholder Yield
0.6%
Dividend + buyback return per year
Buyback Yield
0.6%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
0Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
—
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$60M
Estimated Shares Retired
408.9K
Approx. Share Reduction
0.6%
Shares Outstanding
Current diluted share count from the screening snapshot
70M
At 0.6%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
FAQ
7 questionsPODD Investor Questions
Common questions answered from live analyst data and company financials.
01Is Insulet Corporation (PODD) stock a buy or sell in 2026?
Insulet Corporation (PODD) is rated Buy by Wall Street analysts as of 2026. Of 50 analysts covering the stock, 35 rate it Buy or Strong Buy, 12 rate it Hold, and 3 rate it Sell or Strong Sell. The consensus 12-month price target is $223, implying +53.1% from the current price of $146. The bear case scenario is $177 and the bull case is $371.
02What is the PODD stock price target for 2026?
The Wall Street consensus price target for PODD is $223 based on 50 analyst estimates. The high-end target is $280 (+92.1% from today), and the low-end target is $198 (+35.8%). The base case model target is $282.
03Is Insulet Corporation (PODD) stock overvalued in 2026?
PODD trades at 22.5x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals slightly expensive versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Insulet Corporation (PODD) stock in 2026?
The primary risks for PODD in 2026 are: (1) Revenue growth uncertainty — Despite a projected long-term price increase, the revenue growth forecast of +147. (2) Mixed fundamentals — Insulet Corp. (3) Sector competition — Operating in the competitive Healthcare — Medical Devices sector, Insulet faces risks from established players and innovation pressures. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Insulet Corporation's revenue and earnings forecast?
Analyst consensus estimates PODD will report consensus revenue of $3.3B (+13.5% year-over-year) and EPS of $5.44 (+26.2% year-over-year) for the upcoming fiscal year. The following year, analysts project $3.8B in revenue.
06When does Insulet Corporation (PODD) report its next earnings?
Insulet Corporation is expected to report its next earnings on approximately 2026-08-06. Consensus expects EPS of $1.45 and revenue of $788M. Over recent quarters, PODD has beaten EPS estimates 92% of the time.
07How much free cash flow does Insulet Corporation generate?
Insulet Corporation (PODD) generated $412M in free cash flow over the trailing twelve months — a free cash flow margin of 14.2%. PODD returns capital to shareholders through and share repurchases ($60M TTM).